Reverse genetics [53] have been used to create versions of MV that can specifically target MM via receptors other than CD46 [54,55,56], evade innate immune defenses to prevent viral clearance [57], or express reporter genes for monitoring efficacy of treatment in patients [58,59,60]. Here, CD46 is linked to Miyoshi myopathy.